Ashani T Weeraratna

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7395423/publications.pdf

Version: 2024-02-01

		47006	37204
102	10,242	47	96
papers	citations	h-index	g-index

109	109	109	15976
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A framework for advancing our understanding of cancer-associated fibroblasts. Nature Reviews Cancer, 2020, 20, 174-186.	28.4	2,012
2	Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell, 2002, 1, 279-288.	16.8	859
3	Cancer-Associated Fibroblasts Neutralize the Anti-tumor Effect of CSF1 Receptor Blockade by Inducing PMN-MDSC Infiltration of Tumors. Cancer Cell, 2017, 32, 654-668.e5.	16.8	457
4	How the ageing microenvironment influences tumour progression. Nature Reviews Cancer, 2020, 20, 89-106.	28.4	408
5	AGEMAP: A Gene Expression Database for Aging in Mice. PLoS Genetics, 2007, 3, e201.	3.5	355
6	The Wnt5A/Protein Kinase C Pathway Mediates Motility in Melanoma Cells via the Inhibition of Metastasis Suppressors and Initiation of an Epithelial to Mesenchymal Transition. Journal of Biological Chemistry, 2007, 282, 17259-17271.	3.4	310
7	sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. Nature, 2016, 532, 250-254.	27.8	290
8	Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells. Cancer Cell, 2003, 3, 377-386.	16.8	287
9	Remodeling of the Collagen Matrix in Aging Skin Promotes Melanoma Metastasis and Affects Immune Cell Motility. Cancer Discovery, 2019, 9, 64-81.	9.4	260
10	Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations. Clinical Cancer Research, 2018, 24, 5347-5356.	7.0	253
11	Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors. Journal of Clinical Investigation, 2016, 126, 1834-1856.	8.2	219
12	Hypoxia Induces Phenotypic Plasticity and Therapy Resistance in Melanoma via the Tyrosine Kinase Receptors ROR1 and ROR2. Cancer Discovery, 2013, 3, 1378-1393.	9.4	197
13	PI3K therapy reprograms mitochondrial trafficking to fuel tumor cell invasion. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 8638-8643.	7.1	174
14	Ghrelin promotes thymopoiesis during aging. Journal of Clinical Investigation, 2007, 117, 2778-2790.	8.2	174
15	Metabolic stress regulates cytoskeletal dynamics and metastasis of cancer cells. Journal of Clinical Investigation, 2013, 123, 2907-2920.	8.2	165
16	Modeling the two-way feedback between contractility and matrix realignment reveals a nonlinear mode of cancer cell invasion. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E1617-E1626.	7.1	158
17	Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanoma. Nature Genetics, 2009, 41, 518-520.	21.4	145
18	Rational basis for Trk inhibition therapy for prostate cancer. Prostate, 2000, 45, 140-148.	2.3	112

#	Article	IF	Citations
19	Wnt5A Regulates Expression of Tumor-Associated Antigens in Melanoma via Changes in Signal Transducers and Activators of Transcription 3 Phosphorylation. Cancer Research, 2008, 68, 10205-10214.	0.9	111
20	Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells. Cancer Immunology Research, 2016, 4, 845-857.	3.4	110
21	Personalized Preclinical Trials in BRAF Inhibitorâ€“Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies. Clinical Cancer Research, 2016, 22, 1592-1602.	7.0	108
22	Active Notch1 Confers a Transformed Phenotype to Primary Human Melanocytes. Cancer Research, 2009, 69, 5312-5320.	0.9	103
23	Thapsigargin induces a calmodulin/calcineurin-dependent apoptotic cascade responsible for the death of prostatic cancer cells. Prostate, 2000, 43, 303-317.	2.3	100
24	Age-Related Changes in HAPLN1 Increase Lymphatic Permeability and Affect Routes of Melanoma Metastasis. Cancer Discovery, 2019, 9, 82-95.	9.4	100
25	Polyunsaturated Fatty Acids from Astrocytes Activate PPARÎ³ Signaling in Cancer Cells to Promote Brain Metastasis. Cancer Discovery, 2019, 9, 1720-1735.	9.4	97
26	Alterations in immunological and neurological gene expression patterns in Alzheimer's disease tissues. Experimental Cell Research, 2007, 313, 450-461.	2.6	96
27	PKC and PKA Phosphorylation Affect the Subcellular Localization of Claudin-1 in Melanoma Cells. International Journal of Medical Sciences, 2009, 6, 93-101.	2.5	92
28	Melanoma models for the next generation of therapies. Cancer Cell, 2021, 39, 610-631.	16.8	90
29	Differential LEF1 and TCF4 expression is involved in melanoma cell phenotype switching. Pigment Cell and Melanoma Research, 2011, 24, 631-642.	3.3	81
30	Coâ€targeting <scp>BET</scp> and <scp>MEK</scp> as salvage therapy for <scp>MAPK</scp> and checkpoint inhibitorâ€resistant melanoma. EMBO Molecular Medicine, 2018, 10, .	6.9	79
31	Hear the Wnt Ror: how melanoma cells adjust to changes in Wnt. Pigment Cell and Melanoma Research, 2009, 22, 724-739.	3.3	78
32	<scp>W</scp>nt5<scp>A</scp> promotes an adaptive, senescentâ€like stress response, while continuing to drive invasion in melanoma cells. Pigment Cell and Melanoma Research, 2015, 28, 184-195.	3.3	77
33	Changes in Aged Fibroblast Lipid Metabolism Induce Age-Dependent Melanoma Cell Resistance to Targeted Therapy via the Fatty Acid Transporter FATP2. Cancer Discovery, 2020, 10, 1282-1295.	9.4	75
34	A Wnt-er Wonderlandâ€”The complexity of Wnt signaling in melanoma. Cancer and Metastasis Reviews, 2005, 24, 237-250.	5.9	72
35	Generation and analysis of melanoma SAGE libraries: SAGE advice on the melanoma transcriptome. Oncogene, 2004, 23, 2264-2274.	5.9	71
36	Loss of Klotho during melanoma progression leads to increased filamin cleavage, increased Wnt5A expression, and enhanced melanoma cell motility. Pigment Cell and Melanoma Research, 2011, 24, 175-186.	3.3	68

#	ARTICLE	IF	CITATIONS
37	Stromal changes in the aged lung induce an emergence from melanoma dormancy. Nature, 2022, 606, 396-405.	27.8	67
38	Phenylmethimazole Decreases Toll-Like Receptor 3 and Noncanonical Wnt5a Expression in Pancreatic Cancer and Melanoma Together with Tumor Cell Growth and Migration. Clinical Cancer Research, 2009, 15, 4114-4122.	7.0	64
39	Wnt5A Activates the Calpain-Mediated Cleavage of Filamin A. Journal of Investigative Dermatology, 2009, 129, 1782-1789.	0.7	64
40	Heparan Sulfate Proteoglycan Modulation of Wnt5A Signal Transduction in Metastatic Melanoma Cells. Journal of Biological Chemistry, 2009, 284, 28704-28712.	3.4	63
41	Ghrelin and the Growth Hormone Secretagogue Receptor Constitute a Novel Autocrine Pathway in Astrocytoma Motility*. Journal of Biological Chemistry, 2006, 281, 16681-16690.	3.4	62
42	RAF around the Edges â€” The Paradox of BRAF Inhibitors. New England Journal of Medicine, 2012, 366, 271-273.	27.0	59
43	A Wnt-er Migration: The Confusing Role of Î²-Catenin in Melanoma Metastasis. Science Signaling, 2013, 6, pe11.	3.6	59
44	Activation of Wnt5A signaling is required for CXC chemokine ligand 12â€“mediated T-cell migration. Blood, 2009, 114, 1366-1373.	1.4	58
45	In the Wnt-er of life: Wnt signalling in melanoma and ageing. British Journal of Cancer, 2016, 115, 1273-1279.	6.4	54
46	The State of Melanoma: Emergent Challenges and Opportunities. Clinical Cancer Research, 2021, 27, 2678-2697.	7.0	53
47	The Wnts of change: How Wnts regulate phenotype switching in melanoma. Biochimica Et Biophysica Acta: Reviews on Cancer, 2015, 1856, 244-251.	7.4	52
48	Autophagy- An emerging target for melanoma therapy. F1000Research, 2016, 5, 1888.	1.6	49
49	Gene Expression Profiling: From Microarrays to Medicine. Journal of Clinical Immunology, 2004, 24, 213-224.	3.8	48
50	Paradoxical Role for Wild-Type p53 in Driving Therapy Resistance in Melanoma. Molecular Cell, 2020, 77, 633-644.e5.	9.7	45
51	Striking the target in Wnt-y conditions: Intervening in Wnt signaling during cancer progression. Biochemical Pharmacology, 2010, 80, 702-711.	4.4	44
52	The immunohistochemistry of invasive and proliferative phenotype switching in melanoma: a case report. Melanoma Research, 2010, 20, 349-355.	1.2	43
53	Novel Protein Kinase C-Mediated Control of Orai1 Function in Invasive Melanoma. Molecular and Cellular Biology, 2015, 35, 2790-2798.	2.3	42
54	Genetic screening for single-cell variability modulators driving therapy resistance. Nature Genetics, 2021, 53, 76-85.	21.4	41

#	ARTICLE	IF	CITATIONS
55	CXCL12â€induced partitioning of flotillinâ€1 with lipid rafts plays a role in CXCR4 function. European Journal of Immunology, 2007, 37, 2104-2116.	2.9	40
56	Cyclophilin D Extramitochondrial Signaling Controls Cell Cycle Progression and Chemokine-directed Cell Motility*. Journal of Biological Chemistry, 2013, 288, 5553-5561.	3.4	39
57	Syntaphilin controls a mitochondrial rheostat for proliferation-motility decisions in cancer. Journal of Clinical Investigation, 2017, 127, 3755-3769.	8.2	37
58	Bad company: Microenvironmentally mediated resistance to targeted therapy in melanoma. Pigment Cell and Melanoma Research, 2019, 32, 237-247.	3.3	35
59	HSP70 Inhibition Limits FAK-Dependent Invasion and Enhances the Response to Melanoma Treatment with BRAF Inhibitors. Cancer Research, 2016, 76, 2720-2730.	0.9	33
60	Molecular signature and in vivo behavior of bone marrow endosteal and subendosteal stromal cell populations and their relevance to hematopoiesis. Experimental Cell Research, 2012, 318, 2427-2437.	2.6	32
61	Inhibition of Age-Related Therapy Resistance in Melanoma by Rosiglitazone-Mediated Induction of Klotho. Clinical Cancer Research, 2017, 23, 3181-3190.	7.0	30
62	Transcriptome analysis of age-, gender- and diet-associated changes in murine thymus. Cellular Immunology, 2007, 245, 42-61.	3.0	29
63	Deconstructing tumor heterogeneity: the stromal perspective. Oncotarget, 2020, 11, 3621-3632.	1.8	29
64	When Will Melanoma Vaccines Be Proven Effective?. Journal of Clinical Oncology, 2004, 22, 387-389.	1.6	28
65	Evaluating the impact of age on immune checkpoint therapy biomarkers. Cell Reports, 2021, 36, 109599.	6.4	27
66	Sperm-Derived SPANX-B Is a Clinically Relevant Tumor Antigen That Is Expressed in Human Tumors and Readily Recognized by Human CD4+ and CD8+ T Cells. Clinical Cancer Research, 2009, 15, 1954-1963.	7.0	26
67	ATG5 Mediates a Positive Feedback Loop between Wnt Signaling and Autophagy in Melanoma. Cancer Research, 2017, 77, 5873-5885.	0.9	26
68	Tumour Dormancy and Reawakening: Opportunities and Challenges. Trends in Cancer, 2019, 5, 762-765.	7.4	23
69	SAGE Identification and Fluorescence Imaging Analysis of Genes and Transcripts in Melanomas and Precursor Lesions. Cancer Biology and Therapy, 2004, 3, 104-109.	3.4	22
70	p21 gene knock down does not identify genetic effectors seen with gene knock out. Cancer Biology and Therapy, 2007, 6, 1025-1030.	3.4	22
71	Transcriptome analysis of murine thymocytes reveals age-associated changes in thymic gene expression. International Journal of Medical Sciences, 2009, 6, 51-64.	2.5	22
72	Shared genetic and epigenetic changes link aging and cancer. Trends in Cell Biology, 2022, 32, 338-350.	7.9	20

#	ARTICLE	IF	CITATIONS
73	UV-Induced Wnt7a in the Human Skin Microenvironment Specifies the Fate of Neural Crestâ€"Like Cells via Suppression of Notch. Journal of Investigative Dermatology, 2015, 135, 1521-1532.	0.7	18
74	Trk receptor inhibition induces apoptosis of proliferating but not quiescent human osteoblasts. Cancer Research, 2002, 62, 986-9.	0.9	18
75	Change Is in the Air: The Hypoxic Induction of Phenotype Switching in Melanoma. Journal of Investigative Dermatology, 2013, 133, 2316-2317.	0.7	17
76	Normal Aging and Its Role in Cancer Metastasis. Cold Spring Harbor Perspectives in Medicine, 2020, 10, a037341.	6.2	17
77	sFRP2 Supersedes VEGF as an Age-related Driver of Angiogenesis in Melanoma, Affecting Response to Anti-VEGF Therapy in Older Patients. Clinical Cancer Research, 2020, 26, 5709-5719.	7.0	17
78	The dark side of daylight: photoaging and the tumor microenvironment in melanoma progression. Journal of Clinical Investigation, 2021, 131, .	8.2	17
79	Myeloid-Derived Suppressor Cells Are a Major Source of Wnt5A in the Melanoma Microenvironment and Depend on Wnt5A for Full Suppressive Activity. Cancer Research, 2021, 81, 658-670.	0.9	15
80	Discovering causes and cures for cancer from gene expression analysis. Ageing Research Reviews, 2005, 4, 548-563.	10.9	14
81	ER stress promotes antitumor effects in BRAFi/MEKi resistant human melanoma induced by natural compound 4-nerolidylcathecol (4-NC). Pharmacological Research, 2019, 141, 63-72.	7.1	14
82	Enhancing the evaluation of <scp>PI</scp>3K inhibitors through 3DÂmelanoma models. Pigment Cell and Melanoma Research, 2016, 29, 317-328.	3.3	12
83	Serial Analysis of Gene Expression (SAGE): Advances, Analysis and Applications to Pigment Cell Research. Pigment Cell & Melanoma Research, 2003, 16, 183-189.	3.6	11
84	Bisphosphonamidate Clodronate Prodrug Exhibits Selective Cytotoxic Activity against Melanoma Cell Lines. Molecular Cancer Therapeutics, 2014, 13, 297-306.	4.1	11
85	The Race toward Equity: Increasing Racial Diversity in Cancer Research and Cancer Care. Cancer Discovery, 2020, 10, 1451-1454.	9.4	11
86	A glitch in the matrix: Ageâ€dependent changes in the extracellular matrix facilitate common sites of metastasis. Aging and Cancer, 2020, 1, 19-29.	1.6	11
87	Uteroglobin: A Potential Novel Tumor Suppressor and Molecular Therapeutic for Prostate Cancer. Clinical Prostate Cancer, 2002, 1, 118-124.	2.1	10
88	Automatic detection of melanoma progression by histological analysis of secondary sites. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2012, 81A, 364-373.	1.5	10
89	Women in cancer research. Nature Reviews Cancer, 2019, 19, 547-552.	28.4	10
90	Lack of Wnt5A Expression in Merkel Cell Carcinoma. Archives of Dermatology, 2010, 146, 88-9.	1.4	8

#	Article	IF	Citations
91	HSP70 Inhibition Blocks Adaptive Resistance and Synergizes with MEK Inhibition for the Treatment of <i>NRAS</i>-Mutant Melanoma. Cancer Research Communications, 2021, 1, 17-29.	1.7	5
92	Preserve junior faculty in biomedical sciences during and after the pandemic. Nature Medicine, 2020, 26, 1003-1004.	30.7	4
93	A Series of BRAF- and NRAS-Driven Murine Melanoma Cell Lines with Inducible Gene Modulation Capabilities. JID Innovations, 2022, 2, 100076.	2.4	4
94	UNRelenting Translation UNRestrains Melanoma Migration. Cancer Cell, 2016, 30, 655-657.	16.8	2
95	Meeting report from the 10th International Congress of the Society for Melanoma Research, Philadelphia, PA, November 2013. Pigment Cell and Melanoma Research, 2014, 27, E1-E12.	3.3	1
96	Analysis of immune checkpoint blockade biomarkers in elderly patients using large-scale cancer genomics data.. Journal of Clinical Oncology, 2021, 39, 2543-2543.	1.6	1
97	F.113. Wnt5a Regulates Melanoma Antigen Recognized By T-Cells-1 (Mart-1), a Predominant Antigen in Melanoma Cells. Clinical Immunology, 2006, 119, S90.	3.2	0
98	When metastasis â€˜Spnsâ€™ out of control: Coverage of â€˜Genomeâ€wide in vivo screen identifies novel host regulators of metastatic colonizationâ€™. Pigment Cell and Melanoma Research, 2017, 30, 384-385.	3.3	0
99	Key Signaling Pathways in Normal and Neoplastic Melanocytes. , 2018, , 1-19.		0
100	Key Signaling Pathways in Normal and Neoplastic Melanocytes. , 2019, , 63-81.		0
101	Supporting women in science at <scp>PCMR</scp>. Pigment Cell and Melanoma Research, 2019, 32, 484-485.	3.3	0
102	Completing the Great Unfinished Symphony of Cancer Together: The Importance of Immigrants in Cancer Research. Cancer Cell, 2020, 38, 301-305.	16.8	0